Chugai Pharmaceutical Co Ltd (4519.T)
30 Sep 2016
* Chugai will continue to be responsible for product manufacturing and supply of Nemolizumab.
* Announced that it concluded a license agreement with roche for "sa237"
* Announced results of Japanese phase III study of Alecensa in Alk fusion gene positive non-small cell lung cancer
Earnings vs. Estimates
Analyst Research Reports
Chugai Pharmaceutical Co Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider : Reuters Investment Profile
Provider : GlobalData
Provider : MarketLine
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.